
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

